Free Trial
→ Musk’s Next $4 Trillion Takeover Target – It’s Stranger than you Think (From Banyan Hill Publishing) (Ad)tc pixel Free AVXL Stock Alerts

Anavex Life Sciences (AVXL) Financials

Anavex Life Sciences logo
$3.24 +0.02 (+0.62%)
Closing price 05/11/2026 04:00 PM Eastern
Extended Trading
$3.26 +0.02 (+0.77%)
As of 07:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Anavex Life Sciences

Annual Income Statements for Anavex Life Sciences

This table shows Anavex Life Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 9/30/2014 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024
Net Income / (Loss) Attributable to Common Shareholders		 -9.97 -12 -15 -13 -17 -26 -26 -38 -48 -48 -43
Consolidated Net Income / (Loss)		 -9.97 -12 -15 -13 -17 -26 -26 -38 -48 -48 -43
Net Income / (Loss) Continuing Operations		 -11 -12 -15 -13 -17 -26 -26 -38 -48 -48 -43
Total Pre-Tax Income 		-11 -12 -15 -13 -17 -26 -26 -38 -48 -47 -43
Total Operating Income		 -2.97 -7.11 -16 -16 -19 -29 -31 -42 -51 -56 -53
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 2.97 7.11 16 16 19 29 31 42 51 56 53
Selling, General & Admin Expense		 2.24 4.84 8.33 5.01 5.99 6.85 5.86 9.02 13 12 11
Research & Development Expense		 0.73 2.27 7.25 11 13 22 25 33 38 44 42
Total Other Income / (Expense), net		 -8.40 -5.00 0.88 2.28 2.15 2.89 4.83 4.36 3.37 8.26 9.88
Interest Expense		 8.63 5.07 -0.01 -0.09 -0.22 -0.17 -0.18 -0.03 -0.95 -6.52 -7.32
Interest & Investment Income		 0.00 0.00 0.71 2.16 1.98 2.76 4.38 4.55 3.32 2.72 2.29
Other Income / (Expense), net		 0.23 0.07 0.16 0.03 -0.05 -0.04 0.28 -0.21 -0.90 -0.98 0.26
Income Tax Expense		 0.00 0.00 0.03 0.06 0.07 0.08 0.02 0.27 0.36 0.01 0.00
Basic Earnings per Share		 ($1.02) ($0.65) ($0.42) ($0.33) ($0.39) ($0.54) - - - ($0.60) ($0.52)
Weighted Average Basic Shares Outstanding		 9.80M 18.58M 35.15M 40.84M 44.66M 48.91M -0.45 -0.54 -0.62 79.79M 83.47M
Diluted Earnings per Share		 ($1.02) ($0.65) ($0.42) ($0.33) ($0.39) ($0.54) - - - ($0.60) ($0.52)
Weighted Average Diluted Shares Outstanding		 9.80M 18.58M 35.15M 40.84M 44.66M 48.91M -0.45 -0.54 -0.62 79.79M 83.47M
Weighted Average Basic & Diluted Shares Outstanding		 9.80M 18.58M 35.15M 40.84M 44.66M 48.91M 58.19M -0.54 -0.62 82.09M 84.82M

Quarterly Income Statements for Anavex Life Sciences

This table shows Anavex Life Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -14 -13 -13 -11 -10 -8.62 -11 -12 -12 -12 -11
Consolidated Net Income / (Loss)		 -14 -13 -13 -11 -10 -8.62 -11 -12 -12 -12 -11
Net Income / (Loss) Continuing Operations		 -14 -13 -13 -11 -10 -8.62 -11 -12 -12 -12 -11
Total Pre-Tax Income 		-14 -13 -13 -11 -10 -8.62 -11 -12 -12 -12 -11
Total Operating Income		 -15 -15 -14 -14 -13 -11 -13 -15 -14 -14 -13
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 15 15 14 14 13 11 13 15 14 14 13
Selling, General & Admin Expense		 3.90 3.32 2.88 3.25 2.59 2.69 2.90 2.86 2.78 3.15 2.62
Research & Development Expense		 11 12 11 10 10 8.68 9.73 12 12 10 9.89
Total Other Income / (Expense), net		 1.20 2.39 1.13 2.29 2.44 2.76 2.08 2.45 2.59 1.48 1.32
Interest Expense		 -0.70 -1.27 -1.47 -1.83 -1.96 -2.01 -1.76 -1.86 -1.70 -1.39 -1.21
Interest & Investment Income		 0.99 0.73 0.75 0.57 0.67 0.59 0.47 0.53 0.70 0.41 0.10
Other Income / (Expense), net		 -0.50 0.39 -1.08 -0.10 -0.19 0.16 -0.15 0.07 0.19 -0.33 0.01
Basic Earnings per Share		 - - ($0.17) ($0.14) - ($0.11) ($0.13) ($0.14) - ($0.14) ($0.13)
Weighted Average Basic Shares Outstanding		 -0.62 77.98M 78.30M 80.88M 79.79M 82.08M 82.46M 84.54M 83.47M 84.81M 85.07M
Diluted Earnings per Share		 - - ($0.17) ($0.14) - ($0.11) ($0.13) ($0.14) - ($0.14) ($0.13)
Weighted Average Diluted Shares Outstanding		 -0.62 77.98M 78.30M 80.88M 79.79M 82.08M 82.46M 84.54M 83.47M 84.81M 85.07M
Weighted Average Basic & Diluted Shares Outstanding		 -0.62 77.98M 78.30M -0.14 82.09M 82.11M 84.64M 84.80M 84.82M 85.06M 85.37M

Annual Cash Flow Statements for Anavex Life Sciences

This table details how cash moves in and out of Anavex Life Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 9/30/2014 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024
Net Change in Cash & Equivalents		 6.92 8.03 -6.10 18 -4.51 -0.75 7.06 123 -2.95 1.87 -19
Net Cash From Operating Activities		 -2.66 -4.23 -9.24 -9.02 -13 -19 -21 -30 -24 -28 -31
Net Cash From Continuing Operating Activities		 -2.66 -4.23 -9.24 -9.02 -13 -19 -21 -30 -24 -28 -31
Net Income / (Loss) Continuing Operations		 -9.97 -12 -15 -13 -17 -26 -26 -38 -48 -48 -43
Consolidated Net Income / (Loss)		 -9.97 -12 -15 -13 -17 -26 -26 -38 -48 -48 -43
Non-Cash Adjustments To Reconcile Net Income		 7.92 6.71 4.86 3.99 5.52 6.43 4.88 8.23 18 17 9.36
Changes in Operating Assets and Liabilities, net		 -1.74 1.17 0.64 0.45 -0.85 1.30 0.12 -0.71 5.36 2.51 2.83
Net Cash From Investing Activities		 -0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 -0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 9.58 12 3.13 27 8.07 18 28 153 21 30 12
Net Cash From Continuing Financing Activities		 9.58 12 3.13 27 8.07 18 28 153 21 30 12
Issuance of Common Equity		 0.37 12 3.17 27 8.17 18 29 153 21 28 11
Other Financing Activities, net		 - - - - - - 0.00 5.58 1.01 1.78 0.69

Quarterly Cash Flow Statements for Anavex Life Sciences

This table details how cash moves in and out of Anavex Life Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -4.04 -5.54 9.85 1.35 -3.79 -7.26 -4.38 -0.63 -6.57 -11 -5.00
Net Cash From Operating Activities		 -4.04 -5.79 -8.49 -7.65 -5.85 -7.32 -12 -5.18 -6.66 -12 -5.86
Net Cash From Continuing Operating Activities		 -4.04 -5.79 -8.49 -7.65 -5.85 -7.32 -12 -5.18 -6.66 -12 -5.86
Net Income / (Loss) Continuing Operations		 -14 -13 -13 -11 -10 -8.62 -11 -12 -12 -12 -11
Consolidated Net Income / (Loss)		 -14 -13 -13 -11 -10 -8.62 -11 -12 -12 -12 -11
Non-Cash Adjustments To Reconcile Net Income		 6.04 5.35 4.82 3.87 3.19 2.29 2.65 2.43 2.00 2.06 1.44
Changes in Operating Assets and Liabilities, net		 4.20 1.83 -0.20 -0.24 1.11 -0.98 -3.76 4.61 2.97 -2.06 3.90
Net Cash From Financing Activities		 0.00 0.26 18 9.00 2.06 0.06 7.28 4.55 0.09 0.71 0.85
Net Cash From Continuing Financing Activities		 0.00 0.26 18 9.00 2.06 0.06 7.28 4.55 0.09 0.71 0.85
Other Financing Activities, net		 -0.00 0.26 0.18 0.47 0.87 0.06 0.10 0.44 0.09 0.71 0.85

Annual Balance Sheets for Anavex Life Sciences

This table presents Anavex Life Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 9/30/2014 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024
Total Assets		 7.35 15 9.50 28 26 25 35 162 153 154 136
Total Current Assets		 7.35 15 9.45 28 26 23 30 152 153 152 133
Cash & Equivalents		 7.26 15 9.19 27 23 22 29 152 149 151 132
Prepaid Expenses		 0.09 0.10 0.18 0.34 1.25 0.50 0.44 0.37 0.35 0.65 0.93
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.05 0.05 0.15 2.64 4.85 9.14 0.00 2.71 2.45
Noncurrent Note & Lease Receivables		 - - - - - 2.64 4.85 9.14 - 2.71 2.45
Total Liabilities & Shareholders' Equity		 7.35 15 9.50 28 26 25 35 162 153 154 136
Total Liabilities		 7.16 2.66 3.19 3.58 3.88 5.04 7.31 11 10 13 15
Total Current Liabilities		 1.44 2.66 3.19 3.58 3.88 5.04 7.31 10 9.77 12 14
Accounts Payable		 1.25 2.50 3.12 3.58 2.96 3.52 3.99 4.74 3.83 4.32 9.63
Accrued Expenses		 - - - - 0.93 1.52 3.32 5.61 5.95 7.30 4.84
Total Noncurrent Liabilities		 5.72 0.00 0.00 0.00 0.00 0.00 0.00 0.44 0.44 0.92 0.84
Other Noncurrent Operating Liabilities		 - - - - - - - - 0.44 - 0.84
Commitments & Contingencies		 - 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.19 13 6.31 24 22 20 27 151 142 142 120
Total Preferred & Common Equity		 0.19 13 6.31 24 22 20 27 151 142 142 120
Preferred Stock		 - - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 0.19 13 6.31 24 22 20 27 151 142 142 120
Common Stock		 51 74 84 116 129 154 187 348 388 435 456
Retained Earnings		 -51 -63 -78 -91 -107 -133 -160 -198 -246 -293 -336

Quarterly Balance Sheets for Anavex Life Sciences

This table presents Anavex Life Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025
Period end date 6/30/2022 12/31/2022 3/31/2023 6/30/2023 12/31/2023 3/31/2024 6/30/2024 12/31/2024 3/31/2025
Total Assets		 160 148 159 158 148 145 142 124 117
Total Current Assets		 160 148 159 156 145 141 142 121 117
Cash & Equivalents		 153 144 153 155 144 139 139 121 116
Prepaid Expenses		 0.46 0.66 0.98 0.83 0.76 1.35 1.06 0.71 0.70
Current Deferred & Refundable Income Taxes		 6.56 4.09 4.74 - - - 1.72 - 0.67
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.00 2.17 3.55 3.79 0.00 2.56 0.00
Total Liabilities & Shareholders' Equity		 160 148 159 158 148 145 142 124 117
Total Liabilities		 9.48 13 14 11 12 9.56 12 13 17
Total Current Liabilities		 9.48 12 13 10 12 8.64 11 12 17
Accounts Payable		 3.13 5.29 6.28 4.15 4.29 3.73 3.50 4.57 7.00
Accrued Expenses		 5.91 7.04 6.82 5.99 7.29 4.92 7.33 7.73 9.56
Total Noncurrent Liabilities		 0.00 0.92 0.92 0.92 0.92 0.92 0.92 0.83 0.83
Other Noncurrent Operating Liabilities		 - 0.92 0.92 0.92 0.92 0.92 0.92 0.83 0.83
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 151 135 145 147 136 135 130 111 100
Total Preferred & Common Equity		 151 135 145 147 136 135 130 111 100
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 151 135 145 147 136 135 130 111 100
Common Stock		 382 394 417 430 437 447 454 459 459
Retained Earnings		 -231 -259 -272 -283 -302 -312 -324 -348 -359

Annual Metrics And Ratios for Anavex Life Sciences

This table displays calculated financial ratios and metrics derived from Anavex Life Sciences' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 9/30/2014 9/30/2015 9/30/2016 9/30/2017 9/30/2018 9/30/2019 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 55.80% -336.58% -119.17% -1.49% -23.83% -50.38% -5.71% -37.00% -22.92% -9.34% 7.27%
EBIT Growth		 25.01% -157.22% -119.16% -1.48% -23.83% -50.38% -5.71% -37.00% -22.92% -9.34% 7.27%
NOPAT Growth		 -38.91% -139.43% -119.29% -0.59% -23.30% -50.55% -6.81% -35.11% -21.39% -9.36% 5.16%
Net Income Growth		 -169.41% -21.47% -21.71% 8.66% -28.17% -52.41% 0.06% -44.25% -26.56% 0.99% 9.48%
EPS Growth		 -750.00% 36.27% 35.38% 21.43% -18.18% -38.46% 0.00% 0.00% 0.00% 0.00% 13.33%
Operating Cash Flow Growth		 -242.01% -58.95% -118.52% 2.38% -39.54% -47.25% -14.90% -42.73% 20.23% -14.63% -10.89%
Free Cash Flow Firm Growth		 -136.70% -6.24% -179.07% -2.29% -51.01% -18.48% -13.40% -39.17% -0.63% -20.49% 6.19%
Invested Capital Growth		 55.43% -106.99% -20.12% -10.69% 80.89% -211.35% -6.15% 35.92% -416.97% -37.57% -30.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 65.12% -68.76% -20.10% 12.58% -9.22% -1.63% -5.54% -12.04% -6.67% 4.93% -2.55%
EBIT Q/Q Growth		 40.92% -68.75% -20.10% 12.58% -9.22% -1.63% -5.54% -12.04% -6.67% 4.93% -2.55%
NOPAT Q/Q Growth		 21.83% -87.99% -20.17% 12.83% -9.11% -1.60% -3.88% -12.74% -6.32% 4.51% -3.29%
Net Income Q/Q Growth		 -114.01% 19.55% -8.50% 14.43% -8.49% -0.05% -1.38% -17.89% -5.66% 8.02% -3.55%
EPS Q/Q Growth		 -500.00% 51.85% 14.29% 5.71% 7.14% 3.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -19.41% -13.92% -6.72% -2.00% -17.36% 7.58% -21.18% -4.90% 13.03% -6.95% -2.70%
Free Cash Flow Firm Q/Q Growth		 28.01% -89.28% -24.84% 19.29% -40.07% -2.27% -0.01% -5.32% 3.83% -3.55% 1.89%
Invested Capital Q/Q Growth		 -103.44% -93.03% -46.29% -137.56% 72.84% 47.81% 31.50% -211.27% -170.71% -13.76% -32.86%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 87.69% 100.00% 100.20% 100.44% 100.42% 100.31% 100.09% 100.71% 100.75% 100.01% 100.00%
Interest Burden Percent		 415.47% 172.04% 95.35% 85.61% 88.63% 89.93% 85.22% 89.17% 91.77% 83.72% 81.73%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 878.04% -186.26% -154.17% -88.09% -74.08% -123.42% -110.59% -42.58% -32.72% -33.41% -32.81%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 878.04% -186.26% -154.17% -88.09% -74.08% -123.42% -110.59% -42.58% -32.72% -33.41% -32.81%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -94.53% -233.61% -55.50% -77.29% -129.60% -96.49% -25.14% -33.67% -33.49% -35.76%
Net Operating Profit after Tax (NOPAT)		 -2.08 -4.98 -11 -11 -14 -20 -22 -29 -36 -39 -37
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1,062.95% -86.16% -31.36% -13.56% -14.77% -26.24% -17.57% -9.38% -8.16% -5.65% -4.23%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - -27.51% -30.78%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.74 -7.04 -15 -16 -19 -29 -31 -42 -52 -57 -53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.61 -7.04 -15 -16 -19 -29 -31 -42 -52 -57 -53
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 61.57 2.92 20.55 7.20 5.56 8.20 10.06 9.01 5.65 3.78 4.00
Price to Tangible Book Value (P/TBV)		 61.57 2.92 20.55 7.20 5.56 8.20 10.06 9.01 5.65 3.78 4.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 30.69 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 29.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.65 -1.27 -1.28 -1.20 -1.08 -1.06 -1.08 -1.02 -1.03 -1.06 -1.08
Leverage Ratio		 -3.41 1.76 1.31 1.22 1.16 1.21 1.26 1.10 1.07 1.08 1.11
Compound Leverage Factor		 -14.18 3.02 1.25 1.05 1.03 1.09 1.07 0.98 0.98 0.90 0.90
Debt to Total Capital		 96.84% 0.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 3.15% 0.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 93.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 3.16% 99.34% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -3.67 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.84 2.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -3.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -2.84 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.65 3.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -2.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -9.01 2.18 8.31 23.81 12.01 9.47 13.85 73.99 45.00 22.91 15.18
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.10 5.81 2.96 7.75 6.71 4.50 4.06 14.73 15.63 13.06 9.20
Quick Ratio		 5.04 5.75 2.88 7.66 5.90 4.40 4.00 14.69 15.27 13.00 9.14
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.52 -3.74 -10 -11 -16 -19 -22 -30 -30 -37 -34
Operating Cash Flow to CapEx		 -88,204.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -0.41 -0.74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -0.31 -0.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -0.31 -0.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.16 -2.40 -2.88 -3.19 -0.61 -1.90 -2.01 -1.29 -6.67 -9.17 -12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.44 -1.24 -0.48 -0.31 2.58 -1.29 -0.12 0.72 -5.38 -2.51 -2.75
Enterprise Value (EV)		 11 22 120 147 101 144 245 1,207 655 386 349
Market Capitalization		 12 37 130 175 124 166 274 1,359 804 537 482
Book Value per Share		 $0.01 $0.11 $0.18 $0.58 $0.49 $0.39 $0.45 $1.99 $1.83 $1.73 $1.42
Tangible Book Value per Share		 $0.01 $0.11 $0.18 $0.58 $0.49 $0.39 $0.45 $1.99 $1.83 $1.73 $1.42
Total Capital		 6.10 13 6.31 24 22 20 27 151 142 142 120
Total Debt		 5.91 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 5.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1.35 -15 -9.19 -27 -23 -22 -29 -152 -149 -151 -132
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.16 -2.40 -2.93 -3.24 -0.76 -4.54 -6.86 -9.98 -6.22 -11 -14
Debt-free Net Working Capital (DFNWC)		 6.10 13 6.26 24 22 18 22 142 143 140 119
Net Working Capital (NWC)		 5.91 13 6.26 24 22 18 22 142 143 140 119
Net Nonoperating Expense (NNE)		 7.89 7.13 3.82 2.48 3.72 5.92 4.52 8.51 12 8.48 5.99
Net Nonoperating Obligations (NNO)		 -1.35 -15 -9.19 -27 -23 -22 -29 -152 -149 -151 -132
Total Depreciation and Amortization (D&A)		 1.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.29) ($0.65) ($0.42) ($0.33) ($0.39) ($0.54) ($0.45) ($0.54) $0.00 $0.00 ($0.52)
Adjusted Weighted Average Basic Shares Outstanding		 39.73M 18.58M 35.15M 44.22M 46.59M 56.12M 66.96M 76.02M 77.96M 82.09M 83.47M
Adjusted Diluted Earnings per Share		 ($0.30) ($0.65) ($0.42) ($0.33) ($0.39) ($0.54) ($0.45) ($0.54) $0.00 $0.00 ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding		 39.73M 18.58M 35.15M 44.22M 46.59M 56.12M 66.96M 76.02M 77.96M 82.09M 83.47M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.33) ($0.39) ($0.54) ($0.45) ($0.54) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 54.68M 34.60M 39.61M 40.84M 44.66M 48.91M 58.19M 69.80M 76.91M 82.09M 84.82M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.08 -4.98 -11 -11 -14 -20 -22 -29 -36 -39 -37
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -0.32 -1.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -0.24 -0.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -0.32 -1.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -0.24 -0.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.54% -14.64% -1.47% 0.00% 0.00%

Quarterly Metrics And Ratios for Anavex Life Sciences

This table displays calculated financial ratios and metrics derived from Anavex Life Sciences' official financial filings.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -25.88% -28.50% -35.74% -3.34% 18.64% 25.15% 17.04% -7.56% -10.18% -24.02% 2.13%
EBIT Growth		 -25.88% -28.50% -35.74% -3.34% 18.64% 25.15% 17.04% -7.56% -10.18% -24.02% 2.13%
NOPAT Growth		 -24.74% -31.22% -23.18% -8.61% 17.23% 26.04% 11.78% -8.85% -13.32% -19.46% 0.88%
Net Income Growth		 -21.95% -19.20% -25.57% 8.79% 29.00% 33.53% 19.54% -8.28% -14.53% -40.47% -6.16%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 23.53% 0.00% 0.00% -27.27% 0.00%
Operating Cash Flow Growth		 47.31% -65.50% 11.94% -8.50% -44.63% -26.30% -37.31% 32.31% -13.83% -65.62% 49.76%
Free Cash Flow Firm Growth		 42.78% -57.20% 60.31% 41.97% -19.34% -17.34% -356.45% -142.72% -14.68% 5.17% 122.23%
Invested Capital Growth		 -416.97% -77.83% -629.83% -227.38% -37.57% 3.62% 46.66% -11.32% -30.00% -20.39% -261.63%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -19.62% 4.98% -1.86% 10.74% 5.82% 12.59% -13.76% -15.73% 3.53% 1.61% 10.17%
EBIT Q/Q Growth		 -19.62% 4.98% -1.86% 10.74% 5.82% 12.59% -13.76% -15.73% 3.53% 1.61% 10.17%
NOPAT Q/Q Growth		 -22.68% -0.65% 7.76% 4.64% 6.50% 10.06% -10.86% -17.65% 2.67% 5.19% 7.94%
Net Income Q/Q Growth		 -15.55% 9.23% -1.04% 13.94% 10.05% 15.02% -22.32% -15.82% 4.86% -4.23% 7.56%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 17.65% 0.00% 0.00% 0.00% -7.69% 0.00% 0.00% 7.14%
Operating Cash Flow Q/Q Growth		 42.67% -43.27% -46.51% 9.85% 23.57% -25.12% -59.28% 55.56% -28.53% -82.04% 51.68%
Free Cash Flow Firm Q/Q Growth		 20.25% -32.47% 60.73% -39.85% -64.02% -30.26% -53.87% 25.63% 22.50% -7.71% 136.02%
Invested Capital Q/Q Growth		 -170.71% -27.46% 2.30% 2.88% -13.76% 10.71% 45.93% -102.69% -32.86% 17.31% -62.40%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 101.49% 99.85% 100.38% 100.36% 99.37% 100.00% 101.01% 99.45% 98.95% 100.00% 100.00%
Interest Burden Percent		 89.23% 86.65% 85.50% 82.45% 79.53% 76.83% 82.41% 83.76% 83.02% 87.02% 89.55%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -32.72% -35.57% -35.47% -34.72% -33.41% -31.88% -28.98% -30.03% -32.81% -37.72% -40.17%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -32.72% -35.57% -35.47% -34.72% -33.41% -31.88% -28.98% -30.03% -32.81% -37.72% -40.17%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -37.05% -36.33% -35.19% 0.00% -31.83% -30.08% -32.00% 0.00% -41.92% -47.26%
Net Operating Profit after Tax (NOPAT)		 -11 -11 -9.93 -9.47 -8.86 -7.96 -8.76 -10 -10 -9.51 -8.76
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.38% -1.49% -2.07% -1.17% -0.86% -0.46% -1.22% -1.30% -1.12% -1.96% -1.91%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -6.24% -5.87% - - -8.34% -8.58% -8.78%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -16 -15 -15 -14 -13 -11 -13 -15 -14 -14 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -15 -15 -14 -13 -11 -13 -15 -14 -14 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.65 5.34 4.61 4.48 3.78 5.63 3.10 2.75 4.00 8.21 7.32
Price to Tangible Book Value (P/TBV)		 5.65 5.34 4.61 4.48 3.78 5.63 3.10 2.75 4.00 8.21 7.32
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.05 -1.03 -1.04 -1.06 -1.06 -1.05 -1.06 -1.08 -1.07 -1.09
Leverage Ratio		 1.07 1.08 1.07 1.07 1.08 1.10 1.08 1.08 1.11 1.10 1.11
Compound Leverage Factor		 0.96 0.94 0.92 0.88 0.86 0.84 0.89 0.91 0.92 0.96 1.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 45.78 31.02 27.01 33.98 23.85 34.61 24.02 15.79 16.12 38.39 21.58
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.63 12.03 12.15 15.35 13.06 12.48 16.29 13.06 9.20 9.88 7.08
Quick Ratio		 15.27 11.65 11.71 15.27 13.00 12.42 16.13 12.80 9.14 9.82 6.99
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.32 -7.05 -2.77 -3.87 -6.35 -8.27 -13 -9.40 -7.28 -7.84 2.83
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -6.67 -8.50 -8.30 -8.06 -9.17 -8.19 -4.43 -8.98 -12 -9.86 -16
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -5.38 -3.72 -7.16 -5.60 -2.51 0.31 3.87 -0.91 -2.75 -1.67 -12
Enterprise Value (EV)		 655 578 515 502 386 619 279 218 349 790 614
Market Capitalization		 804 722 669 657 537 763 418 357 482 911 730
Book Value per Share		 $1.83 $1.73 $1.86 $1.82 $1.73 $1.65 $1.64 $1.53 $1.42 $1.31 $1.17
Tangible Book Value per Share		 $1.83 $1.73 $1.86 $1.82 $1.73 $1.65 $1.64 $1.53 $1.42 $1.31 $1.17
Total Capital		 142 135 145 147 142 136 135 130 120 111 100
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -149 -144 -153 -155 -151 -144 -139 -139 -132 -121 -116
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.22 -7.58 -7.39 -9.31 -11 -11 -7.30 -8.06 -14 -12 -15
Debt-free Net Working Capital (DFNWC)		 143 136 146 146 140 133 132 131 119 109 101
Net Working Capital (NWC)		 143 136 146 146 140 133 132 131 119 109 101
Net Nonoperating Expense (NNE)		 3.59 2.20 3.17 1.81 1.29 0.66 1.78 1.90 1.58 2.60 2.44
Net Nonoperating Obligations (NNO)		 -149 -144 -153 -155 -151 -144 -139 -139 -132 -121 -116
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.17) ($0.17) $0.00 $0.00 $0.00 ($0.13) ($0.14) $0.00 ($0.14) ($0.13)
Adjusted Weighted Average Basic Shares Outstanding		 -1.00 78.03M 80.84M 81.95M 79.79M 82.11M 82.46M 84.54M 83.47M 84.81M 85.07M
Adjusted Diluted Earnings per Share		 $0.00 ($0.17) ($0.17) $0.00 $0.00 $0.00 ($0.13) ($0.14) $0.00 ($0.14) ($0.13)
Adjusted Weighted Average Diluted Shares Outstanding		 -1.00 78.03M 80.84M 81.95M 79.79M 82.11M 82.46M 84.54M 83.47M 84.81M 85.07M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.17) ($0.17) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 -1.00 77.98M 78.30M 80.88M 82.09M 82.11M 84.64M 84.80M 84.82M 85.06M 85.37M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -11 -9.93 -9.47 -8.86 -7.96 -8.76 -10 -10 -9.51 -8.76
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are key takeaways for Anavex Life Sciences (AVXL) from the last four years of quarterly filings, focusing on trends in cash flow, income, and balance sheet data.

  • Equity financing inflows have provided liquidity across multiple quarters, including a notable common-equity issuance in 2024-Q3 (+$6.58M) and ongoing financing inflows in 2025 (approx. +$0.7–$0.85M per quarter).
  • Cash and cash equivalents remained substantial, fluctuating roughly from $116M to $156M over the period, with peaks around $154.8M in 2023-Q3 and about $140M in early 2024, and about $115.8M–$121M in 2025 quarters.
  • No reported revenue in the reviewed quarters (Total Revenue = 0.0 across all income statements), indicating the business has not yet monetized its programs.
  • Plant, Property, & Equipment (net) has consistently shown $0.0, suggesting little to no capital expenditures on PP&E during the period.
  • Net income remains negative in every quarter (e.g., -$11.196 million in 2025-Q2), reflecting ongoing losses.
  • Operating cash flow is negative in most quarters (e.g., Net Cash From Continuing Operating Activities -$5.856 million in 2025-Q2), signaling ongoing cash burn from core operations.
  • Retained earnings are deeply negative (e.g., -$359.378 million in 2025-Q2; -$348.182 million in 2025-Q1), indicating substantial cumulative losses funded by equity activity.
  • R&D expenses are consistently a primary cost driver, typically around $9.7–$11.6 million per quarter, contributing importantly to the ongoing losses.
  • Despite occasional financing inflows, the company continues to burn cash with negative overall cash flow, raising runway considerations if the burn rate accelerates or liquidity needs rise.
05/12/26 08:03 AM ETAI Generated. May Contain Errors.

Anavex Life Sciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Anavex Life Sciences' financial year ends in September. Their financial year 2024 ended on September 30, 2024.

Anavex Life Sciences' net income appears to be on an upward trend, with a most recent value of -$43.00 million in 2024, rising from -$9.97 million in 2014. The previous period was -$47.51 million in 2023. See Anavex Life Sciences' forecast for analyst expectations on what's next for the company.

Anavex Life Sciences' total operating income in 2024 was -$52.88 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $52.88 million

Over the last 10 years, Anavex Life Sciences' total revenue changed from $0.00 in 2014 to $0.00 in 2024, a change of 0.0%.

Anavex Life Sciences' total liabilities were at $15.30 million at the end of 2024, a 22.1% increase from 2023, and a 113.7% increase since 2014.

In the past 10 years, Anavex Life Sciences' cash and equivalents has ranged from $7.26 million in 2014 to $152.11 million in 2021, and is currently $132.19 million as of their latest financial filing in 2024.

Over the last 10 years, Anavex Life Sciences' book value per share changed from 0.01 in 2014 to 1.42 in 2024, a change of 28,266.0%.


Related Companies

Financial statements for NASDAQ:AVXL last updated on 6/18/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Read this or regret it forever
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Musk’s Next $4 Trillion Takeover Target – It’s Stranger than you Think
Tech analyst Ian King - who called an early Tesla trade that returned up to 1,000% in just over a year - says ...
Banyan Hill Publishing | Sponsoredtc pixel
Gold Is About to Do Something It Hasn’t in 90 Years
The U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...
US Gold Bureau | Sponsoredtc pixel
Your book attached
Veteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...
Profits Run | Sponsoredtc pixel
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...
Brownstone Research | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...
Eagle Publishing | Sponsoredtc pixel